Volume 14, Issue 4 (Winter 2017)                   Sci J Iran Blood Transfus Organ 2017, 14(4): 325-334 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mahmoodian R, Salimian M, Hamidpour M, Gharehbaghian A. The effect of Platelets desensitization on the levels of residual platelets reactivity in the diabetes mellitus type 2 patients . Sci J Iran Blood Transfus Organ 2017; 14 (4) :325-334
URL: http://bloodjournal.ir/article-1-1130-en.html
The effect of Platelets desensitization on the levels of residual platelets reactivity in the diabetes mellitus type 2 patients
R. Mahmoodian , M. Salimian , M. Hamidpour * , A. Gharehbaghian
Keywords: Key words: ADP, Platelets, Diabetes Mellitus
Full-Text [PDF 578 kb]   (1273 Downloads)     |   Abstract (HTML)  (4592 Views)
Full-Text:   (3383 Views)
     References:
 
 
  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 36(Suppl 1): S62-S69.
  2. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: Lessons from the Botnia study. Diabetes 2000; 49(6): 975-80.
  3. Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010; 7(4): 251-9.
  4. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009; 32(4): 525-7.
  5. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB. Hyperglycaemia: a prothrombotic factor? J Thromb Haemost 2010; 8(8): 1663-9.
  6. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108(12): 1527-32.
  7. Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38(5): 1307-12.
  8. Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb
Haemost 2010; 8(11): 2358-68.
  1. Ferreiro JL, Angiolillo DJ. Diabetes and anti-platelet
therapy in acute coronary syndrome. Circulation 2011;
123(7): 798-813.
  1. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31(1): 15-26.
  2. Buzas EI, György B, Nagy G, Falus A, Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat Rev Rheumatol 2014; 10(6): 356-64.
  3. Morel O, Jesel L, Abbas M, Morel N. Prothrombotic Changes in Diabetes Mellitus. Semin Thromb Hemost 2013; 39(5): 477-88.
  4. Baurand A, Eckly A, Bari N, Léon C, Hechler B, Cazenave JP, et al. Desensitization of the Platelet Aggregation Response to ADP: Differential Down-regulation of the P2Y1 and P2cyc Receptors. Thromb Haemost 2000; 84(3): 489-91.
  5. Siljander PR, Munnix IC, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, et al. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004; 103(4): 1333-41.
  6. Bünemann M, Lee KB, Pals-Rylaarsdam R, Roseberry AG, Hosey MM. Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol 1999; 61: 169-92.
  7. Holme S, Holmsen H. ADP-induced refractory state of platelets in vitro. I. Methodological studies on aggregation in platelet rich plasma. Scand J Haematol 1975; 15(2): 96-103.
  8. Zimmermann H. Nucleotides and cd39: principal modulatory players in hemostasis and thrombosis. Nat Med 1999; 5(9): 987-8.
  9. Mundell SJ, Barton JF, Mayo-Martin MB, Hardy AR, Poole AW. Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemost 2008; 6(8): 1393-404.
  10. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24(8): 1476-85.
  11. Ni H. The platelet “sugar high” in diabetes. Blood 2012; 119(25): 5949-51.
  12. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2(8): 1282-91.
  13. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99(2): 224-9.
  14. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp
    Immunol 2000; 121(3): 437-43.
  15. Yngen M. Platelet function in diabetes mellitus Relationships to hyperglycaemia, antidiabetic treatment and microangiopathy. Solna: Karolinska University Press; 2005; p. 91.
  16. Kakouros N, Rade JJ, Kourliouros A, Resar JR. Platelet Function in Patients with DiabetesMellitus: From a Theoretical to a Practical Perspective. Int J Endocrinol 2011; 2011: 742719.
  17. Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: targets and tools in cardiovascular disease. Trends in Pharmacological Sciences 2011; 32(11): 659-65.
  18. Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost 2005; 94(3): 488-92.
  19. Vajen T, Benedikter BJ, Heinzmann ACA, Vasina EM, Henskens Y, Parsons M, et al. Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype. J Extracell Vesicles 2017; 6(1): 1322454.
  20. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24(8): 1476-85.
  21. Alexandru N, Badila E, Weiss E, Cochior D, Stępień E, Georgescu A. Vascular complications in diabetes: Microparticles and microparticle associated microRNAs as active players. Biochem Biophys Res Commun 2016; 472(1): 1-10.
  22. Pierce GF. Inflammation in nonhealing diabetic wounds: the space-time continuum does matter. Am J Pathol 2001; 159(2): 399-403.
  23. Icli B, Nabzdyk CS, Lujan-Hernandez J, Cahill M, Auster ME, Wara AK, et al. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. J Mol Cell Cardiol 2016; 91: 151-9.
 
 


 
 
 
 
Sci J Iran Blood Transfus Organ 2018; 14(4): 325-334
Original Article
 

 

The effect of Platelets desensitization on the levels
of residual platelets reactivity in the diabetes mellitus
 type 2 patients
 
Mahmoodian R.1, Salimian M.2, Hamidpour M.1,3, Gharehbaghian A.1,4
 
 
1School of Allied Medical Sciences, Shahid  Beheshti University of Medical Sciences, Tehran, Iran
2Faculty of Paramedicine, Kashan University of Medical Sciences and Health Services, Kashan, Iran
3Hemopoietic Stem cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
 
Abstract
Background and Objectives
Patients with diabetes mellitus type 2 have accelerated atherosclerosis. Hyperactive platelets and platelets micro particles play an important role in this prothrombotic state. Desensitization is a physiological process which plays an important role in turning off receptor mediated signal transduction pathways. In this study, we described and compared this process in diabetes mellitus type 2 patients and healthy individuals.
 
Materials and Methods
In this fundamental-applied study, 40 diabetes mellitus type 2 patients and 35 healthy individuals participated in the study. After centrifuging at 200 g, PRP was prepared. Desensitization was induced with mild agonist stimulation and low dose of ADP (1 μM). Expression of platelets CD62P and CD41+- Annexin-v+ micro particles were evaluated by Flow cytometry. Data were analyzed by Anova and t-test.
 
Results
In comparison with healthy individuals, the diabetic group showed a significant increase in expression of CD62P in baseline. Desensitized platelets had less expression of CD62Pb but these platelets produced more micro particles in this state. Diabetic group showed a significant increase in production of platelet micro particles in all of states with ADP treatment. (p ≤ 0.004)
 
Conclusions 
The flow cytometric data show that platelets in patients with diabetes mellitus type 2 patients are hyperactive that it associated to metabolic conditions. Induction of desensitization state helps platelets to reduce platelets activation and platelets sensitivity to ADP in diabetic environment. Also the production of platelets microparticles is high in these patients and desensitized platelets are more susceptible to microparticle shedding.
 
Key words: ADP, Platelets, Diabetes Mellitus
 
 
Received: 21 Jun 2017
Accepted:  4 Jul  2017
 
 

Correspondence: Hamidpour M., PhD of Hematology & Blood Banking. Associate Professor of Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences.
Postal Code: 1971653383, Tehran, Iran. Tel: (+9821) 22717504; Fax: (+9821) 22717504
E-mail:
mohsenhp@sbmu.ac.ir
Type of Study: Research | Subject: Hematology
Published: 2017/12/31
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Scientific Journal of Iran Blood Transfus Organ

Designed & Developed by : Yektaweb